Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study
Why the study?
Does daily low-dose aspirin extend disability-free and dementia-free life in a healthy elderly population?
Population
19,114 healthy elderly participants aged 70+ years or 65+ years free of cardiovascular disease, dementia, or…
Comparison
Aspirin 100-mg enteric-coated daily for 5 years vs Placebo
Design
RCT, Randomized, Double-blind
Follow-up
5 years (planned)
Authors
Discussion
Loading...
Member takes
Implication
Successfully recruited large elderly cohort enables definitive aspirin RCT; confirms feasibility of large-scale geriatric prevention trials.
Structured PICO
Does daily low-dose aspirin extend disability-free and dementia-free life in a healthy elderly population?
P
Population
19,114 healthy elderly participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Median age 74, 56% women.
I
Intervention
Aspirin 100-mg enteric-coated daily for 5 years
C
Comparator
Placebo
O
Outcome
Composite primary endpoint of death, incident dementia or persistent physical disabilitycomposite
The ASPREE trial successfully recruited 19,114 healthy elderly participants to evaluate whether daily low-dose aspirin extends disability-free and dementia-free survival.
Cite This Study
McNeil et al. (2017) studied this question.